PEGylation can improve the therapeutic potential of ribonuclease A (RNase A), a cancer chemotherapeutic agent. However, the common PEGylation that targets at the e-amino groups of proteins can lead to imprecise control of the stoichiometry of the protein-PEG conjugate (i.e., mono-, di- and multi-PEGylated protein). To prepare a PEGylated therapeutic protein, it is desirable that the protein is mono-PEGylated for industrial production, convenient purification and analytical characterization. Here, N-hydroxysuccinimide esters of S-acetylthioacetic acid (SATA) and 2-iminothiolane (IT) were used to introduce thiol groups on RNase A. followed by maleimide chemistry based PEGylation of the thiolated RNase A. Interestingly, the yield of mono-PEGylated RNase A was higher than 60%, and di- or multi-PEGylated RNase A were absent in the PEGylated product. Presumably, the limited number and low solvent accessibility of the introduced thiol group favored mono-PEGylation of RNase A. As compared to the unmodified RNase A. the mono-PEGylated RNase A showed slightly decreased enzymatic activity, increased anti-proliferative ability and unchanged structural properties. Our study is expected to control the PEGylation process and optimize the industrial pharmaceutical production of PEGylated proteins. (C) 2012 Elsevier Ltd. All rights reserved.